A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
For more information about the trial above please contact the study team:
Principal Investigator, John Wrangle, at email@example.com.
Study Coordinator, Alexandra Leitner, at firstname.lastname@example.org, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina